Core Insights - Callan JMB Inc. is expanding its reclamation operations into the food sampling industry, leveraging its expertise in regulated materials to tap into sustainable, high-growth consumer markets [1][4] - The company aims to apply its compliance-driven logistics model to meet the specialized needs of food brands and distributors, enhancing product integrity and traceability [2][4] Industry Context - The food logistics market is valued at over $120 billion globally, with an annual growth rate of 6-10%, providing a strong platform for Callan JMB's expansion into food sampling services [5] - The U.S. specialty food sector is projected to reach $130 billion by 2032, indicating significant growth potential in this area [6] Strategic Partnerships - Callan JMB's expansion is supported by its relationship with Keychain, an AI-powered platform that connects manufacturers with brands and retailers, facilitating faster and more responsible product launches [4][8] - Keychain supports over $1 billion in monthly manufacturing projects, highlighting the scale and impact of this partnership [4] Sustainability Focus - The initiative addresses the growing demand for sustainable packaging and waste-reduction practices in food sampling, filling an accountability gap in the industry [3][5] - Callan JMB's compliance infrastructure is designed to help brands meet sustainability expectations while ensuring product quality [5]

Core Viewpoint - Callan JMB Inc. is expanding its reclamation operations into the food sampling industry through a partnership with Keychain, aiming to enhance compliance and sustainability in this high-growth market [1][2][3]. Company Strategy - The partnership with Keychain, an AI-enabled platform, is part of Callan JMB's growth strategy to penetrate neighboring markets that are experiencing significant growth [2]. - The company is already collaborating with established players in the food sampling sector to improve compliance and sustainability in their distribution models [3]. Management Commentary - CEO Wayne Williams emphasized the importance of compliance infrastructure in ensuring safety and accountability, drawing parallels between the food sampling and pharmaceutical industries [3]. - The initiative aims to reduce waste and protect product quality while meeting consumer expectations, reflecting a broader strategy to apply sustainable logistics across various industries [3]. Recent Earnings - In August 2025, Callan JMB reported a second-quarter loss of $0.31 per share, compared to a loss of $0.04 in the previous year, with revenue of $1.666 million, down from $1.986 million year-over-year [4]. - Despite the earnings report, CJMB shares closed higher by 4.45% at $3.99 [4].

Core Insights - Callan JMB INC. has upgraded its Sentry Monitoring System to version 4.0, enhancing flexibility and accessibility for remote monitoring of temperature-sensitive pharmaceutical products [1][2][4] Product Features - The Sentry Monitoring System allows for 24/7/365 active monitoring, alarm notifications, and compliant reporting data, now with improved accessibility through HTML5, enabling users to manage alarms from any device with a web browser [2][3] - Users can access a consistent interface across various devices, including PCs, Macs, iPhones, Androids, and tablets, allowing for real-time monitoring and management of environmental anomalies in pharmaceutical storage [3] Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [5] - The company emphasizes its expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, aiming to provide a high standard of client experience [5]

Core Insights - Callan JMB INC. is participating in the LD Micro Main Event XIX Conference scheduled for October 19-21, 2025, where they will present on October 21 at 12:00 PM PT [1][2] Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [3] - The company aims to secure medical materials and protect patients and communities by providing compliant, safe, and effective medicines [3] - Callan JMB boasts unparalleled expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness [3] - The company emphasizes a high standard of client experience with customizable interfaces, reliable shipping, and environmentally sustainable specialty packaging [3]

As filed with the U.S. Securities and Exchange Commission on September 19, 2025 Registration No. 333- 289849 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Primary Standard Industrial Classification Code Number) Nevada 7389 99-0931141 (I.R.S. Employer Identification Number) 244 Flightline Drive Spring Branch, Texas 78070-6241 (830) 438-0395 CALLAN JMB INC. (Exact name of registrant as specified in i ...

Core Insights - Callan JMB INC. is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through various logistics services [1][3] - The company will participate in two investment conferences in September 2025, providing opportunities for investor engagement [2] Company Overview - Callan JMB specializes in fulfillment, storage, monitoring, and cold chain logistics services aimed at securing medical materials and ensuring patient safety [3] - The company boasts expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness [3] - Callan JMB emphasizes a high standard of client experience with customizable interfaces and reliable shipping, alongside a commitment to environmental sustainability in packaging [3] Upcoming Events - The H.C. Wainwright 27 Annual Global Investment Conference will take place from September 8-10, 2025, with a presentation available on demand starting September 5, 2025 [2] - The iAccess Alpha Virtual Best Ideas Fall Investment Conference is scheduled for September 16-17, 2025, with a presentation on September 16, 2025, at 10:30 a.m. ET [2] - Management will conduct one-on-one investor meetings during both conferences, with scheduling available through designated representatives [2]

As filed with the U.S. Securities and Exchange Commission on August 25, 2025 Registration No. 333-[●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CALLAN JMB INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 7389 99-0931141 (I.R.S. Employer Identification Number) 244 Flightline Drive Spring Branch, Texas 78070 ...

PART I - FINANCIAL INFORMATION [Item 1. Unaudited Financial Statements](index=3&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) Presents unaudited condensed consolidated financial statements, covering balance sheets, operations, equity, cash flows, and detailed notes [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Summarizes the company's financial position, including assets, liabilities, and equity, as of June 30, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Highlights (June 30, 2025 vs. December 31, 2024) | Metric | June 30, 2025 (USD) | December 31, 2024 (USD) | Change (USD) | Change % | | :-------------------------- | :-------------- | :---------------- | :----- | :------- | | Cash and cash equivalents | $4,224,151 | $2,097,945 | $2,126,206 | 101.3% | | Total assets | $8,965,681 | $5,082,549 | $3,883,132 | 76.4% | | Total liabilities | $3,140,394 | $1,909,191 | $1,231,203 | 64.5% | | Total Stockholders' Equity | $5,825,287 | $3,173,358 | $2,651,929 | 83.6% | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Details the company's revenues, expenses, and net loss for the three and six months ended June 30, 2025 and 2024 Condensed Consolidated Statements of Operations Highlights (Three Months Ended June 30) | Metric | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | Change % | | :---------------------- | :------------ | :------------ | :---------- | :------- | | Revenue | $1,666,309 | $1,985,768 | $(319,459) | -16% | | Gross profit | $643,870 | $962,216 | $(318,346) | -33% | | Loss from operations | $(1,402,667) | $(133,423) | $(1,269,244) | 951% | | Net loss | $(1,397,523) | $(112,476) | $(1,285,047) | 1143% | | Net loss per common share | $(0.31) | $(0.04) | $(0.27) | 675% | Condensed Consolidated Statements of Operations Highlights (Six Months Ended June 30) | Metric | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | Change % | | :---------------------- | :------------ | :------------ | :---------- | :------- | | Revenue | $3,115,687 | $3,776,289 | $(660,602) | -17% | | Gross profit | $1,256,963 | $1,679,799 | $(422,836) | -25% | | Loss from operations | $(2,644,915) | $(220,882) | $(2,424,033) | 1097% | | Net loss | $(2,641,986) | $(193,609) | $(2,448,377) | 1264% | | Net loss per common share | $(0.63) | $(0.08) | $(0.55) | 687.5% | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Outlines changes in stockholders' equity, including net loss, IPO proceeds, and stock-based compensation, from January 1, 2025, to June 30, 2025 Stockholders' Equity Changes (January 1, 2025 to June 30, 2025) | Item | Amount (USD) | | :--------------------------------------- | :----------- | | Stockholders' Equity at January 1, 2025 | $3,173,358 | | Net loss | $(2,638,113) | | Common stock issued in IPO (net of costs)| $3,951,868 | | Common stock issued in IPO (over allotment, net of costs) | $592,120 | | Stock based compensation | $749,927 | | Stockholders' Equity at June 30, 2025 | $5,825,287 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Presents a summary of cash flows from operating, investing, and financing activities for the six months ended June 30, 2025 and 2024 Cash Flow Summary (Six Months Ended June 30) | Activity | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | | :----------------------------- | :------------ | :------------ | :----------- | | Net cash from operating activities | $(2,124,970) | $275,524 | $(2,400,494) | | Net cash used in investing activities | $(447,506) | $(45,874) | $(401,632) | | Net cash from financing activities | $4,698,682 | $(3,537,549) | $8,236,231 | | Cash and cash equivalents at end of period | $4,224,151 | $1,847,721 | $2,376,430 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Provides detailed explanatory notes supporting the condensed consolidated financial statements [NOTE 1 – NATURE OF OPERATIONS](index=8&type=section&id=NOTE%201%20%E2%80%93%20NATURE%20OF%20OPERATIONS) Describes the company's formation, primary operating subsidiary, and its core business in logistics and fulfillment for time-sensitive industries - Callan JMB Inc. was formed on January 24, 2024, in Nevada, to become a holding company for Coldchain Technology Services, LLC (CTS) and Callan JMB Services (India) Private Limited[21](index=21&type=chunk) - CTS, the main operating subsidiary, is engaged in a vertically integrated logistics and fulfillment ecosystem for the supply chain, utilizing advanced predictive technology to ensure product integrity in time-sensitive industries[21](index=21&type=chunk) [NOTE 2 – RECLASSIFICATIONS AND REVISIONS](index=8&type=section&id=NOTE%202%20%E2%80%93%20RECLASSIFICATIONS%20AND%20REVISIONS%20TO%20MARCH%2031%2C%202025%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS) Details immaterial revisions made to previously issued financial statements for the three months ended March 31, 2025 - The Company identified immaterial revisions to its previously issued financial statements for the three months ended March 31, 2025, primarily related to lease modifications and the timing of expense recognition for invoices and prepaid assets[24](index=24&type=chunk) Revisions to March 31, 2025 Consolidated Financial Statements | Financial Statement Line Item | As Previously Reported (USD) | Revisions (USD) | As Revised (USD) | | :-------------------------------- | :--------------------- | :----------- | :----------- | | Right of use asset | $799,739 | $324,352 | $1,124,091 | | Other current assets | $180,328 | $104,106 | $284,434 | | Total Assets | $8,455,666 | $428,458 | $8,884,124 | | Operating lease liabilities – current | $236,343 | $44,453 | $280,796 | | Operating lease liabilities - non-current | $592,587 | $280,924 | $873,511 | | Accrued expenses | $390,461 | $106,954 | $497,415 | | Total Liabilities | $1,648,085 | $432,331 | $2,080,416 | | Retained earnings | $(3,534,238) | $(3,873) | $(3,538,111) | | Total Equity | $6,807,581 | $(3,873) | $6,803,708 | [NOTE 3 – REORGANIZATION](index=8&type=section&id=NOTE%203%20

Executive Summary & Business Update [Company Overview](index=1&type=section&id=1.1%20Company%20Overview) Callan JMB Inc. is an integrative logistics company specializing in fulfillment, storage, monitoring, and cold chain logistics for the healthcare industry and emergency management agencies, focusing on securing medical materials and ensuring patient safety - Callan JMB Inc. provides integrative logistics services, including fulfillment, storage, monitoring, and cold chain logistics, to the healthcare industry and emergency management agencies[2](index=2&type=chunk)[6](index=6&type=chunk) - The company's expertise spans supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness[6](index=6&type=chunk) [Recent Business Highlights](index=1&type=section&id=1.2%20Recent%20Business%20Highlights) Callan JMB announced several key achievements, including a strategic partnership with Revival Health Inc. for integrated supply chain services, the launch of a subsidiary in India for pharmaceutical cold chain logistics, and the extension of a significant emergency preparedness contract with the City of Chicago - Formed a strategic partnership with Revival Health Inc. to deliver fully integrated supply chain services and infrastructure for health, wellness, and longevity products[1](index=1&type=chunk)[7](index=7&type=chunk) - Launched a subsidiary in India (Callan JMB Services (India) Private Limited) and is establishing a temperature-controlled warehouse in Pune, Maharashtra, for pharmaceutical storage and distribution, securing an agreement with Walker's Pharmaceuticals Ltd[1](index=1&type=chunk)[3](index=3&type=chunk)[7](index=7&type=chunk) - Extended the emergency preparedness contract with the City of Chicago through June 2026, with an additional **$1.5 million** in funding, bringing the total contract value to **$9.1 million**[1](index=1&type=chunk)[3](index=3&type=chunk)[7](index=7&type=chunk) - Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs[2](index=2&type=chunk)[7](index=7&type=chunk) - Successfully redistributed over **1,300 MMR II vaccine doses** from Chicago to Texas and New Mexico during a measles outbreak response with zero waste[2](index=2&type=chunk)[3](index=3&type=chunk)[7](index=7&type=chunk) [CEO Commentary](index=1&type=section&id=1.3%20CEO%20Commentary) CEO Wayne Williams highlighted the company's strengthened position in specialized logistics, emphasizing the Revival partnership, international expansion into India to address U.S. drug shortages, and the extended Chicago contract, while also noting the appointment of Christopher Shields to expand emergency preparedness operations and the successful vaccine redistribution, with future growth opportunities in GLP-1 pharmaceutical distribution, specialty compounding pharmacy logistics, and premium food packaging solutions - CEO Wayne Williams emphasized solidifying Callan JMB's position as a leading provider of specialized logistics solutions in high-growth markets[3](index=3&type=chunk) - The strategic partnership with Revival aims to develop a broad supply platform for healthcare products, while the India subsidiary will support global pharmaceutical cold chain logistics and clinical trials, helping address U.S. drug shortages[3](index=3&type=chunk) - The extension of the emergency preparedness contract with the City of Chicago and the appointment of Christopher Shields are intended to grow emergency preparedness operations into new U.S. and international markets[3](index=3&type=chunk) - Future growth opportunities include GLP-1 pharmaceutical distribution, specialty compounding pharmacy logistics, and premium food packaging solutions[3](index=3&type=chunk) Financial Performance Overview [Second Quarter and Six Months Ended June 30, 2025 Financial Highlights](index=2&type=section&id=2.1%20Second%20Quarter%20and%20Six%20Months%20Ended%20June%2030%2C%202025%20Financial%20Highlights) Callan JMB reported revenues of **$1.7 million** for Q2 2025 and **$3.1 million** for the six months ended June 30, 2025, experiencing a year-over-year decrease primarily due to reduced demand for emergency preparedness services, with gross profit for the quarter at **$0.6 million** and **$1.3 million** for the six months, while SG&A expenses significantly increased due to public entity costs and new senior staff hires, leading to an increased loss from operations Key Financial Highlights (Q2 & H1 2025 vs. Prior Year) | Metric | Three months ended June 30, 2025 ($) | Three months ended June 30, 2024 ($) | Six months ended June 30, 2025 ($) | Six months ended June 30, 2024 ($) | | :--------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Revenue | $1.7 million | $2.0 million | $3.1 million | $3.8 million | | Cost of revenues | $1.0 million | $1.0 million | $1.9 million | $2.1 million | | Gross profit | $0.6 million | $1.0 million | $1.3 million | $1.7 million | | SG&A expenses | $2.0 million | $1.1 million | $3.9 million | $1.9 million | | Loss from operations | $(1.4) million | $(0.1) million | $(2.6) million | $(0.2) million | | Cash and cash equivalents (period end) | $4.2 million (June 30, 2025) | - | - | - | - The year-over-year decrease in revenue was attributed to a decline in demand for emergency preparedness services from certain states and local governments[7](index=7&type=chunk) - The increase in SG&A expenses was primarily driven by consulting, professional fees, and marketing expenses related to the Company becoming a public entity and new senior staff hires[7](index=7&type=chunk) - Subsequent to quarter end, the Company entered into an equity line of credit agreement for the right to sell up to **$25 million** of common stock[7](index=7&type=chunk) Condensed Consolidated Financial Statements [Condensed Consolidated Balance Sheets](index=4&type=section&id=3.1%20Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, Callan JMB's total assets increased significantly to **$8.97 million** from **$5.08 million** at December 31, 2024, primarily driven by an increase in cash and cash equivalents and right-of-use assets, while total liabilities also rose to **$3.14 million** from **$1.91 million**, and total stockholders' equity increased to **$5.83 million** from **$3.17 million** Condensed Consolidated Balance Sheet Highlights | Metric | June 30, 2025 (Unaudited) ($) | December 31, 2024 ($) | | :-------------------------- | :-------------------------- | :------------------ | | Cash and cash equivalents | $4,224,151 | $2,097,945 | | Total current assets | $5,590,248 | $3,319,188 | | Total assets | $8,965,681 | $5,082,549 | | Total current liabilities | $1,311,439 | $1,274,315 | | Total liabilities | $3,140,394 | $1,909,191 | | Total Stockholders' Equity | $5,825,287 | $3,173,358 | - Total assets increased by approximately **$3.88 million** from December 31, 2024, to June 30, 2025[11](index=11&type=chunk) - The increase in total stockholders' equity was largely due to an increase in additional paid-in capital from **$5.46 million** to **$10.76 million**[11](index=11&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=3.2%20Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, revenue decreased to **$1.67 million** from **$1.99 million** year-over-year, resulting in a gross profit of **$0.64 million**, while selling, general, and administrative expenses significantly increased, leading to a net loss of **$(1.40) million**, or **$(0.31)** per share, compared to a net loss of **$(0.11) million**, or **$(0.04)** per share, in the prior year's quarter, with similar trends observed for the six-month period Condensed Consolidated Statements of Operations Highlights | Metric | Three months ended June 30, 2025 ($) | Three months ended June 30, 2024 ($) | Six months ended June 30, 2025 ($) | Six months ended June 30, 2024 ($) | | :----------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Revenue | $1,666,309 | $1,985,768 | $3,115,687 | $3,776,289 | | Cost of revenue | $1,022,439 | $1,023,552 | $1,858,724 | $2,096,490 | | Gross profit | $643,870 | $962,216 | $1,256,963 | $1,679,799 | | Selling, general and administrative expenses | $2,046,537 | $1,095,639 | $3,901,878 | $1,900,681 | | Loss from operations | $(1,402,667) | $(133,423) | $(2,644,915) | $(220,882) | | Net loss | $(1,397,523) | $(112,476) | $(2,641,986) | $(193,609) | | Net loss per common share - basic and diluted | $(0.31) | $(0.04) | $(0.63) | $(0.08) | - Revenue decreased by **16.09%** for the three months and **17.49%** for the six months ended June 30, 2025, compared to the prior year periods[13](index=13&type=chunk) - Selling, general and administrative expenses increased by **86.79%** for the three months and **105.29%** for the six months ended June 30, 2025, compared to the prior year periods[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=3.3%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities was **$(2.12) million**, a significant change from net cash provided of **$0.28 million** in the prior year, primarily due to the increased net loss and stock-based compensation, while investing activities used **$(0.45) million**, mainly for property and equipment purchases, and financing activities provided **$4.70 million**, driven by proceeds from an IPO and overallotment, resulting in a net increase in cash and cash equivalents of **$2.13 million** Condensed Consolidated Statements of Cash Flows Highlights | Metric | Six months ended June 30, 2025 ($) | Six months ended June 30, 2024 ($) | | :------------------------------------------ | :----------------------------- | :----------------------------- | | Net cash provided by (used in) operating activities | $(2,124,970) | $275,524 | | Net cash used in investing activity | $(447,506) | $(45,874) | | Net cash provided by (used in) financing activities | $4,698,682 | $(3,537,549) | | Increase (decrease) in cash and cash equivalents | $2,126,206 | $(3,307,899) | | Cash and cash equivalents at end of period | $4,224,151 | $1,847,721 | - The significant increase in cash from financing activities was primarily due to **$4.68 million** in proceeds from the IPO and overallotment[15](index=15&type=chunk) - Stock-based compensation of **$749,927** was a non-cash adjustment reconciling net loss to operating cash flow for the six months ended June 30, 2025[15](index=15&type=chunk) Additional Information [Forward-Looking Statements](index=3&type=section&id=4.1%20Forward-Looking%20Statements) This section contains a standard disclaimer regarding forward-looking statements, noting that such statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, and the company disclaims any obligation to revise these statements - The press release includes forward-looking statements, identified by words like 'believe,' 'anticipate,' 'expect,' and 'will,' which are not historical facts[8](index=8&type=chunk) - These statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from anticipated outcomes[8](index=8&type=chunk) - The Company disclaims any intention or obligation to revise any forward-looking statements[8](index=8&type=chunk) [Investor Contacts](index=3&type=section&id=4.2%20Investor%20Contacts) Contact information for investor inquiries is provided, directing interested parties to Valter Pinto, Managing Director at KCSA Strategic Communications - Investor inquiries can be directed to Valter Pinto, Managing Director at KCSA Strategic Communications[9](index=9&type=chunk) - Contact details include email: CallanJMB@kcsa.com and phone: 212.896.1254[9](index=9&type=chunk)

Core Viewpoint - Callan JMB Inc. has made significant strides in expanding its logistics services for the healthcare sector, including forming strategic partnerships, launching international operations, and enhancing emergency preparedness capabilities, positioning itself for sustained growth in high-demand markets [2][3]. Business Highlights - A strategic partnership was formed with Revival Health Inc. to create an integrated supply chain infrastructure for health, wellness, and longevity products, enhancing distribution capabilities [2][3]. - The company launched a subsidiary in India, establishing a temperature-controlled warehouse in Pune for pharmaceutical storage and distribution, and has secured agreements with local companies to facilitate U.S. market entry [2][3]. - Callan JMB extended its emergency preparedness contract with the City of Chicago through June 2026, increasing total contract value to $9.1 million with an additional $1.5 million in funding [2][3]. - Christopher Shields was appointed as Senior Vice President for Emergency Preparedness & Response/Government Affairs to expand operations into new markets [2][3]. - The company successfully redistributed over 1,300 MMR II vaccine doses during a measles outbreak response, demonstrating its logistical efficiency and sustainability [2][3]. Financial Highlights - For the three months ended June 30, 2025, revenues were $1.7 million, a decrease from $2.0 million in the same period last year, attributed to reduced demand for emergency preparedness services [8][10]. - Gross profit for the same period was $0.6 million, down from $1.0 million year-over-year [8][11]. - Selling, general, and administrative expenses increased to $2.0 million for the quarter, primarily due to costs associated with being a public entity and new senior staff hires [8][11]. - The net loss for the three months ended June 30, 2025, was $1.4 million, compared to a loss of $0.1 million in the prior year [8][11]. - Cash and cash equivalents as of June 30, 2025, were $4.2 million, an increase from $2.1 million at the end of the previous year [8][13].